Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti‐Activin A): Results From a First‐in‐Human Phase 1 Study

We describe outcomes from the first‐in‐human study of garetosmab (a fully human monoclonal antibody that inhibits activin A) under development for the treatment of fibrodysplasia ossificans progressiva (FOP). In a double‐blind, placebo‐controlled phase 1 study, 40 healthy women of nonchildbearing po...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanhoutte, Frédéric, Liang, Su, Ruddy, Marcella, Zhao, An, Drewery, Tiera, Wang, Yuhuan, DelGizzi, Richard, Forleo‐Neto, Eduardo, Rajadhyaksha, Manoj, Herman, Gary, Davis, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586962/
https://www.ncbi.nlm.nih.gov/pubmed/32557665
http://dx.doi.org/10.1002/jcph.1638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586962/
https://www.ncbi.nlm.nih.gov/pubmed/32557665
http://dx.doi.org/10.1002/jcph.1638

Ejemplares similares